These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 25676691)

  • 21. Unlocking Hope: Anti-VEGFR inhibitors and their potential in glioblastoma treatment.
    Berro A; Assi A; Farhat M; Hatoum L; Saad JP; Mohanna R; Bechara AMA; Prince G; Hachem MCR; Zalaquett Z; Kourie HR
    Crit Rev Oncol Hematol; 2024 Jun; 198():104365. PubMed ID: 38677355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adult mouse subventricular zones stimulate glioblastoma stem cells specific invasion through CXCL12/CXCR4 signaling.
    Goffart N; Kroonen J; Di Valentin E; Dedobbeleer M; Denne A; Martinive P; Rogister B
    Neuro Oncol; 2015 Jan; 17(1):81-94. PubMed ID: 25085362
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastoma.
    Kessler T; Sahm F; Blaes J; Osswald M; Rübmann P; Milford D; Urban S; Jestaedt L; Heiland S; Bendszus M; Hertenstein A; Pfenning PN; Ruiz de Almodóvar C; Wick A; Winkler F; von Deimling A; Platten M; Wick W; Weiler M
    Oncotarget; 2015 Oct; 6(31):31050-68. PubMed ID: 25682871
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transcription factor RUNX2 up-regulates chemokine receptor CXCR4 to promote invasive and metastatic potentials of human gastric cancer.
    Guo ZJ; Yang L; Qian F; Wang YX; Yu X; Ji CD; Cui W; Xiang DF; Zhang X; Zhang P; Wang JM; Cui YH; Bian XW
    Oncotarget; 2016 Apr; 7(15):20999-1012. PubMed ID: 27007162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting AGTR1/NF-κB/CXCR4 axis by miR-155 attenuates oncogenesis in glioblastoma.
    Singh A; Srivastava N; Yadav A; Ateeq B
    Neoplasia; 2020 Oct; 22(10):497-510. PubMed ID: 32896760
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients.
    Lefort S; Thuleau A; Kieffer Y; Sirven P; Bieche I; Marangoni E; Vincent-Salomon A; Mechta-Grigoriou F
    Oncogene; 2017 Mar; 36(9):1211-1222. PubMed ID: 27669438
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma.
    Gravina GL; Mancini A; Marampon F; Colapietro A; Delle Monache S; Sferra R; Vitale F; Richardson PJ; Patient L; Burbidge S; Festuccia C
    J Hematol Oncol; 2017 Jan; 10(1):5. PubMed ID: 28057017
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
    Batchelor TT; Duda DG; di Tomaso E; Ancukiewicz M; Plotkin SR; Gerstner E; Eichler AF; Drappatz J; Hochberg FH; Benner T; Louis DN; Cohen KS; Chea H; Exarhopoulos A; Loeffler JS; Moses MA; Ivy P; Sorensen AG; Wen PY; Jain RK
    J Clin Oncol; 2010 Jun; 28(17):2817-23. PubMed ID: 20458050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
    Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
    World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma.
    Barone A; Sengupta R; Warrington NM; Smith E; Wen PY; Brekken RA; Romagnoli B; Douglas G; Chevalier E; Bauer MP; Dembowsky K; Piwnica-Worms D; Rubin JB
    Oncotarget; 2014 Oct; 5(20):9811-22. PubMed ID: 25238146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Initial testing of the VEGFR inhibitor AZD2171 by the pediatric preclinical testing program.
    Maris JM; Courtright J; Houghton PJ; Morton CL; Gorlick R; Kolb EA; Lock R; Tajbakhsh M; Reynolds CP; Keir ST; Wu J; Smith MA
    Pediatr Blood Cancer; 2008 Mar; 50(3):581-7. PubMed ID: 17457854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single agent efficacy of the VEGFR kinase inhibitor axitinib in preclinical models of glioblastoma.
    Lu L; Saha D; Martuza RL; Rabkin SD; Wakimoto H
    J Neurooncol; 2015 Jan; 121(1):91-100. PubMed ID: 25213669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
    Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
    Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor.
    Nakagawa T; Matsushima T; Kawano S; Nakazawa Y; Kato Y; Adachi Y; Abe T; Semba T; Yokoi A; Matsui J; Tsuruoka A; Funahashi Y
    Cancer Sci; 2014 Jun; 105(6):723-30. PubMed ID: 24689876
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bevacizumab for glioblastoma refractory to vascular endothelial growth factor receptor inhibitors.
    Goldlust SA; Cavaliere R; Newton HB; Hsu M; Deangelis LM; Batchelor TT; Gilbert MR; Lassman AB
    J Neurooncol; 2012 Apr; 107(2):407-11. PubMed ID: 22203237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with glioblastoma.
    Lu-Emerson C; Duda DG; Emblem KE; Taylor JW; Gerstner ER; Loeffler JS; Batchelor TT; Jain RK
    J Clin Oncol; 2015 Apr; 33(10):1197-213. PubMed ID: 25713439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the Response of Intracranial Xenografts to VEGF Signaling Inhibition Using Multiparametric MRI.
    Boult JKR; Box G; Vinci M; Perryman L; Eccles SA; Jones C; Robinson SP
    Neoplasia; 2017 Sep; 19(9):684-694. PubMed ID: 28780387
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
    Ciardiello F; Bianco R; Caputo R; Caputo R; Damiano V; Troiani T; Melisi D; De Vita F; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2004 Jan; 10(2):784-93. PubMed ID: 14760102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CXCR4 increases in-vivo glioma perivascular invasion, and reduces radiation induced apoptosis: A genetic knockdown study.
    Yadav VN; Zamler D; Baker GJ; Kadiyala P; Erdreich-Epstein A; DeCarvalho AC; Mikkelsen T; Castro MG; Lowenstein PR
    Oncotarget; 2016 Dec; 7(50):83701-83719. PubMed ID: 27863376
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gefitinib promotes CXCR4-dependent epithelial to mesenchymal transition via TGF-β1 signaling pathway in lung cancer cells harboring EGFR mutation.
    Zhu Q; Zhang Z; Lu C; Xu F; Mao W; Zhang K; Shou H; Liu Z; Gu J; Ge D
    Clin Transl Oncol; 2020 Aug; 22(8):1355-1363. PubMed ID: 31900845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.